We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
During a House of Commons Health and Social Care Committee witness session on the availability of Vertex’s Orkambi and other cystic fibrosis (CF) drugs on the National Health Service (NHS)